Galena Biopharma Stock Price, News & Analysis (NASDAQ:GALE)

$0.31 0.00 (0.00 %)
(As of 12/18/2017 07:40 AM ET)
Previous Close$0.32
Today's Range$0.28 - $0.33
52-Week Range$0.26 - $3.60
Volume1.52 million shs
Average Volume1.07 million shs
Market Capitalization$14.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.99

About Galena Biopharma (NASDAQ:GALE)

Galena Biopharma logoGalena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Receive GALE News and Ratings via Email

Sign-up to receive the latest news and ratings for GALE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GALE
CUSIPN/A
Phone855-855-4253

Debt

Debt-to-Equity RatioN/A
Current Ratio0.95%
Quick Ratio0.95%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.32 million
Price / Sales1.52
Cash FlowN/A
Price / CashN/A
Book Value$1.89 per share
Price / Book0.16

Profitability

Trailing EPS($1.31)
Net Income$-23,540,000.00
Net MarginsN/A
Return on Equity-92.98%
Return on Assets-33.83%

Miscellaneous

Employees14
Outstanding Shares45,710,000

Galena Biopharma (NASDAQ:GALE) Frequently Asked Questions

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the NASDAQ under the ticker symbol "GALE."

How were Galena Biopharma's earnings last quarter?

Galena Biopharma, Inc. (NASDAQ:GALE) posted its earnings results on Wednesday, May, 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.13. During the same period in the previous year, the business posted ($0.07) EPS. View Galena Biopharma's Earnings History.

Where is Galena Biopharma's stock going? Where will Galena Biopharma's stock price be in 2017?

2 Wall Street analysts have issued 1-year target prices for Galena Biopharma's shares. Their forecasts range from $4.00 to $4.00. On average, they expect Galena Biopharma's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Galena Biopharma.

Who are some of Galena Biopharma's key competitors?

Who are Galena Biopharma's key executives?

Galena Biopharma's management team includes the folowing people:

  • Sanford J. Hillsberg J.D., Chairman of the Board (Age 67)
  • Stephen F. Ghiglieri, Interim Chief Executive Officer, Executive Vice President, Principal Accounting Officer (Age 55)
  • Thomas J. Knapp, Interim General Counsel, Corporate Secretary (Age 63)
  • William L. Ashton, Independent Director (Age 65)
  • Richard H. Chin M.D., Independent Director (Age 49)
  • Irving M. Einhorn, Independent Director (Age 74)
  • Stephen S. Galliker CPA, Independent Director (Age 69)
  • Mary Ann Gray Ph.D., Independent Director (Age 64)

Who owns Galena Biopharma stock?

Galena Biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Vaughan David Investments Inc. IL (2.25%). Company insiders that own Galena Biopharma stock include Hudson Bay Capital Management and Rudolph Nisi. View Institutional Ownership Trends for Galena Biopharma.

Who bought Galena Biopharma stock? Who is buying Galena Biopharma stock?

Galena Biopharma's stock was acquired by a variety of institutional investors in the last quarter, including Vaughan David Investments Inc. IL. View Insider Buying and Selling for Galena Biopharma.

How do I buy Galena Biopharma stock?

Shares of Galena Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galena Biopharma's stock price today?

One share of Galena Biopharma stock can currently be purchased for approximately $0.31.

How big of a company is Galena Biopharma?

Galena Biopharma has a market capitalization of $14.40 million and generates $9.32 million in revenue each year. The biotechnology company earns $-23,540,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Galena Biopharma employs 14 workers across the globe.

How can I contact Galena Biopharma?

Galena Biopharma's mailing address is 2000 Crow Canyon Place Suite 380, San Ramon CA, 94583. The biotechnology company can be reached via phone at 855-855-4253 or via email at [email protected]


MarketBeat Community Rating for Galena Biopharma (GALE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  453
MarketBeat's community ratings are surveys of what our community members think about Galena Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galena Biopharma (NASDAQ:GALE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.202.202.33
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.78$3.37$3.37$3.47
Price Target Upside: 629.66% upside783.99% upside783.99% upside189.44% upside

Galena Biopharma (NASDAQ:GALE) Consensus Price Target History

Price Target History for Galena Biopharma (NASDAQ:GALE)

Galena Biopharma (NASDAQ:GALE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Maxim GroupReiterated RatingHoldHighView Rating Details
2/6/2017FBR & CoDowngradeOutperform -> Market Perform$11.00 -> $4.00N/AView Rating Details
9/20/2016S&P Equity ResearchLower Price Target$0.39 -> $0.34N/AView Rating Details
6/29/2016Noble FinancialDowngradeBuy -> HoldN/AView Rating Details
6/29/2016Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
6/9/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
1/22/2016OppenheimerReiterated RatingOutperform$4.00N/AView Rating Details
(Data available from 12/18/2015 forward)

Earnings

Galena Biopharma (NASDAQ:GALE) Earnings History and Estimates Chart

Earnings by Quarter for Galena Biopharma (NASDAQ:GALE)

Galena Biopharma (NASDAQ GALE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.15)($0.16)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.22)($0.09)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.05)($0.02)ViewListenView Earnings Details
8/9/2016Q216($0.06)$0.05ViewN/AView Earnings Details
5/10/2016Q1($0.06)($0.07)ViewListenView Earnings Details
3/10/2016Q4($0.05)($0.07)$2.61 millionViewListenView Earnings Details
11/9/2015Q315($0.07)($0.11)$4.22 millionViewListenView Earnings Details
8/6/2015Q215($0.09)($0.07)$3.54 million$3.38 millionViewN/AView Earnings Details
5/7/2015Q115($0.09)($0.08)$3.47 million$2.75 millionViewListenView Earnings Details
3/5/2015Q414($0.12)($0.09)$2.58 million$3.20 millionViewN/AView Earnings Details
11/3/2014Q314($0.13)($0.05)$2.66 million$1.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.17)$2.99 million$2.30 millionViewN/AView Earnings Details
5/6/2014Q1($0.10)($0.10)$2.09 million$2.17 millionViewN/AView Earnings Details
3/17/2014Q413($0.09)($0.46)$1.62 million$1.32 millionViewN/AView Earnings Details
8/8/2013Q213($0.10)($0.11)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.62)($0.53)ViewN/AView Earnings Details
11/13/2012Q312($0.09)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Galena Biopharma (NASDAQ:GALE) Earnings Estimates

2017 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.98)($0.98)($0.98)
Q2 20171($0.94)($0.94)($0.94)
Q3 20171($0.50)($0.50)($0.50)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galena Biopharma (NASDAQ:GALE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Galena Biopharma (NASDAQ GALE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 19.00%
Insider Trades by Quarter for Galena Biopharma (NASDAQ:GALE)
Institutional Ownership by Quarter for Galena Biopharma (NASDAQ:GALE)

Galena Biopharma (NASDAQ GALE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/20/2017Rudolph NisiDirectorSell500$0.55$275.00View SEC Filing  
2/8/2017Hudson Bay Capital ManagementMajor ShareholderSell2,363,441$0.84$1,985,290.44View SEC Filing  
2/12/2014Richard ChinDirectorSell187,500$4.33$811,875.00View SEC Filing  
2/7/2014Rudolph NisiDirectorBuy20,000$4.94$98,800.00View SEC Filing  
1/30/2014Mark SchwartzCOOSell100,000$5.57$557,000.00View SEC Filing  
1/30/2014Sanford HillsbergDirectorSell250,000$5.41$1,352,500.00View SEC Filing  
1/29/2014Rudolph NisiDirectorSell250,000$5.28$1,320,000.00View SEC Filing  
1/22/2014Steven KriegsmanDirectorSell450,000$6.52$2,934,000.00View SEC Filing  
1/17/2014Rudolph NisiDirectorSell200,000$6.90$1,380,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Galena Biopharma (NASDAQ GALE) News Headlines

Source:
DateHeadline
Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote - GlobeNewswire (press release)Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote - GlobeNewswire (press release)
globenewswire.com - December 15 at 10:13 AM
Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to VoteGalena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote
finance.yahoo.com - December 14 at 5:39 PM
 Brokerages Expect Galena Biopharma, Inc. (GALE) Will Post Earnings of -$0.15 Per Share Brokerages Expect Galena Biopharma, Inc. (GALE) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - December 14 at 1:30 PM
Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 2017 - GlobeNewswire (press release)Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 2017 - GlobeNewswire (press release)
globenewswire.com - December 9 at 5:00 PM
Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 2017Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 2017
finance.yahoo.com - December 8 at 5:00 PM
Where Galena Biopharma Inc (GALE) Stands In Terms Of Earnings Growth Against Its IndustryWhere Galena Biopharma Inc (GALE) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - November 30 at 5:03 PM
BRIEF-Galena Biopharma posts Q3 loss $0.15/shr from continuing operationsBRIEF-Galena Biopharma posts Q3 loss $0.15/shr from continuing operations
www.reuters.com - November 11 at 12:38 PM
Galena Biopharma Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Galena Biopharma Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 10 at 3:51 PM
Galena Biopharma Reports Third Quarter 2017 Financial ResultsGalena Biopharma Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 10 at 3:51 PM
Galena Biopharma reports 3Q lossGalena Biopharma reports 3Q loss
finance.yahoo.com - November 10 at 3:51 PM
Abbott Laboratories (ABT) vs. Galena Biopharma (GALE) Head to Head AnalysisAbbott Laboratories (ABT) vs. Galena Biopharma (GALE) Head to Head Analysis
www.americanbankingnews.com - November 4 at 1:24 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Galena Biopharma, Inc. - GALE - PR Newswire (press release)SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Galena Biopharma, Inc. - GALE - PR Newswire (press release)
www.prnewswire.com - November 1 at 1:11 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Galena Biopharma, Inc. - GALESHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Galena Biopharma, Inc. - GALE
finance.yahoo.com - October 31 at 8:04 PM
Reviewing Galena Biopharma (GALE) & Its PeersReviewing Galena Biopharma (GALE) & Its Peers
www.americanbankingnews.com - October 31 at 8:58 AM
Critical Survey: Galena Biopharma (GALE) vs. Its PeersCritical Survey: Galena Biopharma (GALE) vs. Its Peers
www.americanbankingnews.com - October 25 at 11:34 PM
Galena Biopharma (GALE) vs. Its Peers Critical ContrastGalena Biopharma (GALE) vs. Its Peers Critical Contrast
www.americanbankingnews.com - October 24 at 10:06 PM
Comparing Galena Biopharma (GALE) & Its RivalsComparing Galena Biopharma (GALE) & Its Rivals
www.americanbankingnews.com - October 21 at 8:15 AM
Head-To-Head Contrast: Galena Biopharma (GALE) & The CompetitionHead-To-Head Contrast: Galena Biopharma (GALE) & The Competition
www.americanbankingnews.com - October 20 at 10:30 PM
Is Galena Biopharma Inc’s (GALE) Balance Sheet A Threat To Its Future?Is Galena Biopharma Inc’s (GALE) Balance Sheet A Threat To Its Future?
finance.yahoo.com - October 20 at 7:59 PM
BRIEF-Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreementBRIEF-Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreement
www.reuters.com - October 18 at 8:22 PM
Critical Contrast: Galena Biopharma (GALE) vs. Novartis AG (NVS)Critical Contrast: Galena Biopharma (GALE) vs. Novartis AG (NVS)
www.americanbankingnews.com - October 15 at 6:33 PM
Form 4 Galena Biopharma, Inc. For: Oct 10 Filed by: GRAY MARY ANN - StreetInsider.comForm 4 Galena Biopharma, Inc. For: Oct 10 Filed by: GRAY MARY ANN - StreetInsider.com
www.streetinsider.com - October 12 at 1:49 AM
Galena Biopharma (GALE) Reports Completion of Enrollment in Two NeuVax (nelipepimut-S) Clinical Trials in Combination with TrastuzumabGalena Biopharma (GALE) Reports Completion of Enrollment in Two NeuVax (nelipepimut-S) Clinical Trials in Combination with Trastuzumab
www.streetinsider.com - September 29 at 2:29 PM
Galena Biopharma Announces Completion of Enrollment in Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with TrastuzumabGalena Biopharma Announces Completion of Enrollment in Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with Trastuzumab
globenewswire.com - September 28 at 6:10 PM
BRIEF-Galena Biopharma announces completion of enrollment in two NeuVax™ clinical trials in combination with TrastuzumabBRIEF-Galena Biopharma announces completion of enrollment in two NeuVax™ clinical trials in combination with Trastuzumab
www.reuters.com - September 28 at 6:10 PM
Galena Biopharma (GALE) Says Nasdaq Notified it of Additional 180-day Grace Period to Regain Compliance with Minimum Bid Price RequirementGalena Biopharma (GALE) Says Nasdaq Notified it of Additional 180-day Grace Period to Regain Compliance with Minimum Bid Price Requirement
www.streetinsider.com - September 26 at 6:57 PM
Galena Biopharma (GALE) Says Nasdaq Notified it of Additional 180-day Grace Period to Regain Compliance with ... - StreetInsider.comGalena Biopharma (GALE) Says Nasdaq Notified it of Additional 180-day Grace Period to Regain Compliance with ... - StreetInsider.com
www.streetinsider.com - September 25 at 5:27 PM
How Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio? - Yahoo FinanceHow Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio? - Yahoo Finance
finance.yahoo.com - September 21 at 12:55 AM
How Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio?How Does Investing In Galena Biopharma Inc (GALE) Impact Your Portfolio?
finance.yahoo.com - September 20 at 7:54 PM
Stock Performance Review on Biotech Industry -- Galena Biopharma, Idera Pharma, Ignyta, and Jaguar HealthStock Performance Review on Biotech Industry -- Galena Biopharma, Idera Pharma, Ignyta, and Jaguar Health
www.marketwatch.com - September 18 at 6:31 PM
Form 425 Galena Biopharma, Inc. Filed by: Galena Biopharma, Inc. - StreetInsider.comForm 425 Galena Biopharma, Inc. Filed by: Galena Biopharma, Inc. - StreetInsider.com
www.streetinsider.com - September 15 at 12:35 AM
Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership - GlobeNewswire (press release)Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership - GlobeNewswire (press release)
www.globenewswire.com - September 12 at 12:28 AM
BRIEF-Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnershipBRIEF-Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership
www.reuters.com - September 11 at 7:26 PM
Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 PartnershipGalena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership
finance.yahoo.com - September 11 at 7:26 PM
UPDATE 1-Galena settles US kickback charges related to opioid drug - Business InsiderUPDATE 1-Galena settles US kickback charges related to opioid drug - Business Insider
www.businessinsider.com - September 9 at 6:24 PM
UPDATE 1-Galena settles US kickback charges related to opioid drug - ReutersUPDATE 1-Galena settles US kickback charges related to opioid drug - Reuters
www.reuters.com - September 9 at 5:35 AM
BRIEF-U.S. DOJ says Galena Biopharma to pay over $7.55 mln to resolve alleged claimsBRIEF-U.S. DOJ says Galena Biopharma to pay over $7.55 mln to resolve alleged claims
www.reuters.com - September 8 at 7:23 PM
Galena settles U.S. kickback charges related to opioid drugGalena settles U.S. kickback charges related to opioid drug
finance.yahoo.com - September 8 at 7:23 PM
Head-To-Head Analysis: Eyegate Pharmaceuticals (EYEG) & Galena Biopharma (GALE)Head-To-Head Analysis: Eyegate Pharmaceuticals (EYEG) & Galena Biopharma (GALE)
www.americanbankingnews.com - September 2 at 2:26 AM
Galena Biopharma, Inc. (GALE) Expected to Post Earnings of -$0.15 Per ShareGalena Biopharma, Inc. (GALE) Expected to Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - August 23 at 10:20 PM
Galena Biopharma Inc (GALE) Announces  Earnings ResultsGalena Biopharma Inc (GALE) Announces Earnings Results
www.americanbankingnews.com - August 15 at 1:54 PM
Earnings Reaction History: Galena Biopharma, Inc., 80.0% Follow-Through Indicator, 5.6% Sensitive - NasdaqEarnings Reaction History: Galena Biopharma, Inc., 80.0% Follow-Through Indicator, 5.6% Sensitive - Nasdaq
www.nasdaq.com - August 14 at 7:14 PM
Galena Biopharma Reports Second Quarter 2017 Financial ResultsGalena Biopharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 7:14 PM
Galena Biopharma reports 2Q lossGalena Biopharma reports 2Q loss
finance.yahoo.com - August 14 at 7:14 PM
Galena Biopharma (NASDAQ:GALE) versus Neos Therapeutics (NEOS) Critical SurveyGalena Biopharma (NASDAQ:GALE) versus Neos Therapeutics (NEOS) Critical Survey
www.americanbankingnews.com - August 11 at 10:52 PM
The Rosen Law Firm, P.A. Announces Proposed Settlement with Remaining Defendants in Galena Biopharmaceutical Securities LitigationThe Rosen Law Firm, P.A. Announces Proposed Settlement with Remaining Defendants in Galena Biopharmaceutical Securities Litigation
www.bizjournals.com - August 11 at 7:21 PM
Galena Biopharma (GALE) Discusses Galena Biopharma and SELLAS Life Sciences Group Merger Call (Transcript)Galena Biopharma (GALE) Discusses Galena Biopharma and SELLAS Life Sciences Group Merger Call (Transcript)
seekingalpha.com - August 11 at 7:21 PM
Maxim Group Reaffirms Hold Rating for Galena Biopharma, Inc. (NASDAQ:GALE)Maxim Group Reaffirms Hold Rating for Galena Biopharma, Inc. (NASDAQ:GALE)
www.americanbankingnews.com - August 9 at 6:46 PM
SELLAS Life Sciences to merge with Galena in all-stock deal - Seeking AlphaSELLAS Life Sciences to merge with Galena in all-stock deal - Seeking Alpha
seekingalpha.com - August 9 at 4:40 AM
Galena Biopharma Enters into Merger Agreement with SELLAS Life ... - GlobeNewswire (press release)Galena Biopharma Enters into Merger Agreement with SELLAS Life ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 4:40 AM

SEC Filings

Galena Biopharma (NASDAQ:GALE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galena Biopharma (NASDAQ:GALE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galena Biopharma (NASDAQ GALE) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.